Vivani Medical Arranges $5.1 Million for Semaglutide Implant
Vivani Medical expects $5.1 million in gross proceeds from a 5,049,506-share placement, with two directors buying at $1.01 ahead of a planned 2027 Phase 2 study.
By Amara Osei
3 min read

What's News
- The private placement is expected to generate approximately $5.1 million in gross proceeds before offering expenses.
- Gregg Williams and Aaron Mendelsohn agreed to purchase 5,049,506 shares at $1.01 per share.
- The placement is expected to close on or around November 23, 2026, subject to customary closing conditions.
- SLIM-1 enrolled 20 participants: 10 received NPM-139 and 10 received 0.25-milligram weekly injectable semaglutide.
- Vivani plans a Phase 2 dose-ranging weight-maintenance study in 2027 and expects operations funded into the third quarter of 2027.
By Amara Osei
Vivani Medical expects a private placement to generate approximately $5.1 million in gross proceeds before offering expenses, the company said. The agreement covers 5,049,506 shares of Vivani common stock at $1.01 per share and remains subject to customary closing conditions.
Board Chairman Gregg Williams and director Aaron Mendelsohn agreed to purchase 5,049,506 shares, according to Vivani Medical. The transaction was priced at the market under applicable Nasdaq rules. Vivani expects the placement to close on or around November 23, 2026, after satisfaction of customary closing conditions.
What does the $5.1 million financing fund?
Vivani Medical said it will use the net proceeds to fund research and clinical development of NPM-139, its semaglutide implant. The company also plans to support other product candidates with the financing. A portion of the money will go to working capital and general corporate needs.
Vivani expects the placement proceeds, combined with its existing cash, cash equivalents and restricted cash, to fund operations into the third quarter of 2027. The $5.1 million figure represents gross proceeds before offering expenses, not cash earmarked solely for NPM-139. Vivani did not specify a dollar allocation among research, other candidates, working capital and general corporate needs.
Its runway projection combines the new placement with cash, cash equivalents and restricted cash already held. That makes the financing part of a broader liquidity plan rather than a dedicated NPM-139 allocation, according to Vivani.
What did the Phase 1 trial show?
The financing followed Vivani’s announcement of positive top-line results from SLIM-1, its first human Phase 1 study of NPM-139. The four-week, open-label, active-controlled trial enrolled 20 overweight or obese participants, the company said.
Vivani divided the study into two groups of 10:
- 10 participants received a low dose of NPM-139.
- 10 participants received the initial 0.25-milligram weekly dose of injectable semaglutide.
The injectable semaglutide arm served as the active comparator in SLIM-1, Vivani said. Both study arms therefore used semaglutide-based interventions over the same four-week period. The trial enrolled 20 overweight or obese participants.
How did the safety results compare?
Vivani reported no treatment-related adverse events among participants who received NPM-139. Five participants in the injectable semaglutide control group experienced treatment-related gastrointestinal events. No serious adverse events were reported in the study, the company said.
Implant insertion and removal procedures were completed without complications, according to Vivani. Vivani cited the results as support for a Phase 2 dose-ranging study in weight maintenance.
Across the full cohort, Vivani reported no serious adverse events. The procedural results covered both insertion and removal, which Vivani described as completed without complications. Those details sit alongside the reported absence of treatment-related adverse events in the NPM-139 arm.
What comes after SLIM-1?
Vivani said the Phase 1 results support plans for a Phase 2 dose-ranging study of NPM-139 in weight maintenance. The company anticipates beginning that study in 2027. The planned study will evaluate a range of doses, according to Vivani’s description.
Vivani’s NanoPortal platform is designed to deliver medicines steadily through miniature implants administered once or twice per year, the company said. Its pipeline focuses on GLP-1 therapies for obesity and Type 2 diabetes.
Vivani’s next stated milestone is a 2027 Phase 2 start for NPM-139, while the company expects financing and existing liquidity to sustain operations into the third quarter of 2027. The Phase 2 start will test Vivani’s ability to advance NPM-139 while operating within that projected funding horizon.
Source: pulse2.com
More from Amara Osei
Show full bio
Senior reporter covering companies, deals and strategy in entrepreneurship, startups and venture funding at Business Bearings.
2,175 articles